Association of tumor necrosis factor alpha -308 single nucleotide polymorphism with SARS CoV-2 infection in an Iraqi Kurdish population

Hussein N. Ali1 | Sherko S. Niranji1,2,3 | Sirwan M. A. Al-Jaf1,2,3

INTRODUCTION

Coronavirus disease 2019 (Covid-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS CoV-2), has been considered as a pandemic and public health threat. The immunopathogenesis of Covid-19 requires outstanding research to uncover the reasons behind the severity of the disease in some Covid-19 patients while it is mild or asymptomatic in others. It is known that SARS CoV-2 enters into human cells via interactions between human angiotensin-converting enzyme 2 receptor (ACE2) and viral spike protein. Additionally, SARS CoV-2 initiates both innate and adaptive immune response through pattern recognition receptors and cytokines, particularly proinflammatory cytokines including interleukin-1 beta (IL-1β), interleukin-6 (IL-6), interleukin-8 (IL-8), and tumor necrosis factor-alpha (TNF-α), which lead to cytokine storm, acute respiratory distress syndrome (ARDS) and death in some Covid-19 patients.1,2 Researchers have been continuously looking for discovering risk factors that can be connected to the disease. At the first step, it was suggested that individuals, who are old, male and have previous cardiovascular problems, severely acquire the disease. Furthermore, it...
was also noticed that genetic variations in human genes (e.g., ACE2, TMPRSS2, cytokines, TLR-7, androgen receptor, and protease genes) may also be related to Covid-19 severity. Consequently, candidate genes, including genetic variants in cytokines, chemokines, and receptors, were selected based on their previous associations with SARS-CoV-1, SARS-CoV-2, and other infectious diseases. The candidate genes include variations in ABO blood groups, human leukocyte antigen (HLA loci; type I interferon-related genes (e.g., TLR3, TLR4, UNC93B1, TBK1, IRF7, IFNAR2, OAS, IFITM3, and PRKRA); cytokines (e.g., TNF-α, TEMEM189-UBE2V1, IL-17A, and WSB1; chemokines (e.g., CCR2, CCR5, CCR9, CXCR6, and XCR1; and other genes (e.g., DPP7, DPP9, MST1R, GOLGA3, GOLGA8B, LAPT4B, and ApoE). Consequently, Covid-19 Host Genetics Initiative (HGI) announced a global project collaborating among researchers to discover genetic loci in various populations. Analyzing three meta-analysis studies using approximately 50 thousand people from 19 countries, the HGI project has found 13 genetic loci associated with Covid-19. These loci and their closest genes are highlighted (rs2271616: SLC6A20), (rs10490770: L2ZTL1), (s11919389: RPL24), (rs1886614: FOXP4), (rs72711165: TEMEM65), (rs912805253: ABO), (rs10774671: OAS1), (rs77534576: TAC4), (rs1819040: KANS1L1), (rs2109069: DPP9), (rs74956615: RAVER1), (rs4801778: PLEKHA4), and (rs13050728: IFNAR2). Whole-genome sequences of thousand Covid patients have discovered associations between Covid-19 infections and variants in genes including IL10RB and PLSCR (interferon signaling), BCL11A (leukocyte differentiation), FUT2 (blood type antigen secretor status). In a recent systematic review, the TNF-α gene was considered as one of the most important candidate genes which are potentially associated with progressions of Covid-19.

Tumor necrosis factor alpha (TNF-α) gene is located on chromosome 6p21.33 and encodes TNF-α protein secreted by macrophages and expressed in most organ tissue including lungs. The TNF-α gene was also noticed that genetic variations in human genes (e.g., ACE2, TMPRSS2, cytokines, TLR-7, androgen receptor, and protease genes) may also be related to Covid-19 severity. Consequently, candidate genes, including genetic variants in cytokines, chemokines, and receptors, were selected based on their previous associations with SARS-CoV-1, SARS-CoV-2, and other infectious diseases. The candidate genes include variations in ABO blood groups, human leukocyte antigen (HLA loci; type I interferon-related genes (e.g., TLR3, TLR4, UNC93B1, TBK1, IRF7, IFNAR2, OAS, IFITM3, and PRKRA); cytokines (e.g., TNF-α, TEMEM189-UBE2V1, IL-17A, and WSB1; chemokines (e.g., CCR2, CCR5, CCR9, CXCR6, and XCR1; and other genes (e.g., DPP7, DPP9, MST1R, GOLGA3, GOLGA8B, LAPT4B, and ApoE). Consequently, Covid-19 Host Genetics Initiative (HGI) announced a global project collaborating among researchers to discover genetic loci in various populations. Analyzing three meta-analysis studies using approximately 50 thousand people from 19 countries, the HGI project has found 13 genetic loci associated with Covid-19. These loci and their closest genes are highlighted (rs2271616: SLC6A20), (rs10490770: L2ZTL1), (s11919389: RPL24), (rs1886614: FOXP4), (rs72711165: TEMEM65), (rs912805253: ABO), (rs10774671: OAS1), (rs77534576: TAC4), (rs1819040: KANS1L1), (rs2109069: DPP9), (rs74956615: RAVER1), (rs4801778: PLEKHA4), and (rs13050728: IFNAR2). Whole-genome sequences of thousand Covid patients have discovered associations between Covid-19 infections and variants in genes including IL10RB and PLSCR (interferon signaling), BCL11A (leukocyte differentiation), FUT2 (blood type antigen secretor status). In a recent systematic review, the TNF-α gene was considered as one of the most important candidate genes which are potentially associated with progressions of Covid-19.

Tumor necrosis factor alpha (TNF-α) gene is located on chromosome 6p21.33 and encodes TNF-α protein secreted by macrophages and expressed in most organ tissue including lungs. The TNF-α gene was considered as one of the most important candidate genes which are potentially associated with progressions of Covid-19.

In the Middle East, particularly in Iraq, studying genetic polymorphisms linking with Covid-19 infection has been unobserved. Before the Covid-19 pandemic emerged, our group has been working on genetic polymorphisms in both Toll-like receptor-4 (TLR4) and Apolipoprotein Epsilon (ApoE) in a general Kurdish population. Lately, we have found that ApoE4 allele is associated with Covid-19 infection in this population. Recent studies have found that TNF-α −308 G>A and TNF receptors are associated with Covid-19 infections in Egyptian and Mexican populations, respectively. Up to our best knowledge, no studies were conducted on the association of this TNF SNP with Covid-19 in other ethnic backgrounds. This study aims to reveal the association of TNF-α −308 G>A SNP with Covid-19 patients in the Iraqi Kurdish population.

### 2 | MATERIALS AND METHODS

#### 2.1 | Sample collections

One hundred and twenty-five (125) blood samples were also collected in Covid-19 patients, whose real-time reverse transcriptase polymerase chain reaction (rRT PCR) was positive and seeking treatment in Kalar Polyclinics, Kurdistan Regional Government, Iraq. The unvaccinated, symptomatic, and Iraqi Kurdish patients...
were included in this study. Both verbal and written consent forms were taken from the patients in a questionnaire form. The patients’ clinical information is shown in Table 1. In the retropective studies performed by our group\textsuperscript{18,30}, one hundred and fourteen (114) EDTA conserved blood samples (3 ml) were taken in a general Iraqi Kurdish population as a reference control. This study was ethically approved by the Department of Biology, University of Garmian, Kurdistan Region. The ethical approval committee adheres to the ethical principles of the Declaration of Helsinki for human subjects.

2.2 Genomic nucleic acid extraction

Total genomic DNA was extracted from the blood samples as described by the manufacturer’s instructions (GENET BIO). 200 µl of DNA was acquired for each sample and kept at −20°C until polymerase chain reaction and genotyping were performed.

2.3 Polymerase chain reaction (PCR)

A partial DNA sequence of the TNF-α gene, where −308G>A SNP is located, was amplified using a pair of primers as previously described\textsuperscript{22} and shown in Table 2. The PCR reaction was as follows: PCR master mix (10 µl) (AddBIO), genomic DNA (4 µl), 10 µM of each primer (0.5 µl). The PCR condition was as follows: initial denaturation at 95°C for 10 min; 35 cycles of (95°C for 45 s, 65°C for 60 s and 72°C for 60 s); and final extension step at 72°C for 10 min using a thermal cycler (Mastercycler nexus, Eppendorf AG). The amplified PCR product (195 bp) was checked on 3% agarose gel and kept at −20°C until genotyping was conducted.

2.4 Genotyping of TNF-α −308G>A

The amplified PCR products were digested using Ncol restriction enzyme (NEB). The reactions were performed as follows: molecular grade water (10 µl), Ncol buffer (4 µl), Ncol enzyme (10 units) and PCR product (10 µl) incubated at 37°C for 3 h using the thermal cycler. The digested PCR products were inspected on 3% agarose gel. The mutant genotypes were repeated at least twice.

2.5 Statistical analysis

The differences in the frequency of the TNF-α genotypes and alleles between both Covid-19 and general population samples were analyzed using Chi-square (Fisher’s exact test) and t test (Graphpad prism 9.1.1 software GraphPad Software). p-values of more than 0.05 were regarded as statistically significant and both odds ratio and confidence interval (% 95 CI) were also used.

3 RESULTS

The Covid-19 patients were mostly symptomatic which were indicated by clinical parameters including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), D-dimer, Ferritin, CT scan, and SpO2 (Table 1). More than half of the patients had comorbidities including obesity, asthma, diabetes, hypertension, ischemic heart disease, and stroke. Among the comorbidities, both hypertension and obesity were the most common in the Covid-19 patients. Data also contained both old and young ages, males and females.

The PCR products of both the general population and Covid-19 patients were observed on agarose gel electrophoresis. As shown in Table 2, a single PCR product band, 195, 173, and 195 bp appeared for each the undigested, homozygous wildtype (GG), and homozygous mutant (AA) genotypes, respectively. Also two bands, 173 and 195 pb appeared for the heterozygous (GA) genotype. As shown in Table 3, the heterozygous genotype (GA) of TNF-α −308G>A was significantly higher in Covid-19 patients than the general population, whereas other genotypes and alleles were not statistically significant. There are no significant differences between the ratio of males to females between both the general population and COVID-19 patients. However, there is a highly significant difference between the ages of the studied groups.

Comparisons of both genotypes and allele frequencies between mild and moderate-severe cases were also non-significant (Table 4). Similarly, no statistically significant differences were found in both genotypes and allele frequencies between genders (Table 5). Based on ages, data were broken down to young ages (<45 years old) and old ages (>45 years old) and the results showed that there are no statistical differences between young and old ages (Table 6). As displayed in Table 7, there were no significant differences in both genotypes and allele frequencies in TNF-α −308G>A in Covid-19 patients who had comorbidities or with no comorbidities.

| Primers | Sequences 5′-3′ | Undigested (bp) | Homozygous Wildtype (bp) | Homozygous mutant (bp) | Heterozygous (bp) |
|---------|-----------------|------------------|-------------------------|------------------------|-------------------|
| TNF-F   | GGAGGCAATAGGTTTTGAGGGCCAT | 195             | 173                     | 195                    | 173 and 195       |
| TNF-R   | CTGCTCT-CGGTTTTCTTCTCATGGGCGG |                   |                         |                        |                   |

Note: Sizes of the PCR products (bp) are shown.

Abbreviations: bp, base pair; TNF-F, forward primer; TNF-R, reverse primer.
| Genotypes | General population n = 114 | COVID−19 n = 125 | p-Value | Odds ratio | 95% CI* |
|-----------|---------------------------|------------------|---------|------------|---------|
| Gender    | Male (46), female (68)    | Male (58), female (67) | 0.4365  | 0.8103     | 0.4826–1.350 |
| Age       | Mean + SD (25.92 ± 7.30)  | Mean + SD (49.19 ± 16.8) | <0.0001 | df = 226  | 19.91–26.64 |
| GG        | 93                        | 87               | 0.4314  | 0.5038     | 0.2696–0.9417 |
| GA        | 17                        | 37               | 0.0342* | 0.5829     | 0.3046–1.111  |
| AA        | 4                         | 1                | 0.2004  | 4.386      | 0.7089–54.04  |

| Alleles General population n = 228 | COVID−19 n = 250 | p-Value | Odds ratio | 95% CI* |
|-----------------------------------|------------------|---------|------------|---------|
| G                                 | 203              | 211     | 0.7370     | 0.8119–1.371 |
| A                                 | 25               | 39      | 0.2300     | 0.4189–1.205 |

*Confidence intervals.
*Standard deviation.
*Degree of freedom.
*Significant.

| Genotypes | Mild N = 73 | Moderate-severe n = 52 | p-Value | Odds ratio | 95% CI |
|-----------|-------------|-------------------------|---------|------------|--------|
| GG n = 87 | 51          | 36                      | >0.9999 | 1.009      | 0.5768–1.786 |
| GA n = 37 | 21          | 16                      | 0.8523  | 0.9349     | 0.4608–1.987 |
| AA n = 1  | 1           | 0                       | >0.9999 | 2.143      | 0.08561–53.64 |

| Alleles Mild n = 146 | Moderate-severe n = 104 | p-Value | Odds ratio | 95% CI |
|----------------------|--------------------------|---------|------------|--------|
| G n = 211            | 123                      | >0.9999 | 0.9954     | 0.6870–1.442 |
| A n = 39             | 23                       | >0.9999 | 1.016      | 0.5159–2.001 |

| Genotypes | Male N = 58 | Female n = 67 | p-Value | Odds ratio | 95% CI |
|-----------|-------------|---------------|---------|------------|--------|
| GG n = 87 | 42          | 45            | 0.8888  | 1.078      | 0.6221–1.867 |
| GA n = 37 | 16          | 21            | 0.8513  | 0.8801     | 0.4157–1.778 |
| AA n = 1  | 0           | 1             | >0.9999 | 0.000      | 0.000–10.55 |

| Alleles Male n = 116 | Female n = 134 | p-Value | Odds ratio | 95% CI |
|----------------------|---------------|---------|------------|--------|
| G n = 211            | 100           | 0.8518  | 1.041      | 0.7195–1.505 |
| A n = 39             | 16            | 0.6056  | 0.8036     | 0.4182–1.550 |

| Genotypes | Age below 45 N = 55 | Age above 45 n = 70 | p-Value | Odds ratio | 95% CI |
|-----------|---------------------|---------------------|---------|------------|--------|
| GG n = 87 | 40                  | 47                  | 0.7809  | 1.083      | 0.6217–1.881 |
| GA n = 37 | 15                  | 22                  | 0.8504  | 0.8678     | 0.3993–1.764 |
| AA n = 1  | 0                   | 1                   | >0.9999 | 0.000      | 0.000–11.62 |

| Alleles Age below 45 n = 110 | Age above 45 n = 140 | p-Value | Odds ratio | 95% CI |
|------------------------------|----------------------|---------|------------|--------|
| G n = 211                    | 95                   | 116     | 0.8511     | 1.042  | 0.7182–1.512 |
| A n = 39                     | 15                   | 24      | 0.6033     | 0.7955 | 0.4031–1.541 |
TABLE 7 Genotypes and allele frequencies of TNF-α −308G>A in Covid-19 patients according to comorbidities

| Genotypes | No comorbidities $N = 67$ | With comorbidities $n = 45$ | $p$-Value | Odds ratio | 95% CI |
|-----------|---------------------------|-----------------------------|-----------|------------|--------|
| GG $n = 87$ | 46 | 41 | >0.9999 | 0.9712 | 0.5611−1.686 |
| GA $n = 37$ | 20 | 17 | >0.9999 | 1.018 | 0.5032−2.117 |
| AA $n = 1$ | 1 | 0 | >0.9999 | Infinity | 0.09477 to Infinity |

| Alleles | No comorbidities $n = 134$ | With comorbidities $n = 116$ | $p$-Value | Odds ratio | 95% CI |
|---------|---------------------------|-----------------------------|-----------|------------|--------|
| G $n = 211$ | 112 | 99 | 0.9256 | 0.9793 | 0.6772−1.417 |
| A $n = 39$ | 22 | 17 | 0.8631 | 1.120 | 0.5811−2.275 |

4 | DISCUSSION

This study aimed to find associations of TNF-α −308G>A SNP with Covid-19 infection. The results of this study showed that the heterozygous (GA) genotype (29.6%) was significantly ($p$-value = 0.0342) associated with Covid-19 infection (Table 3). Saleh, et al. have reported that the mutant homozygous (AA) genotype (80.0%), but not the wildtype homozygous (GG) genotype, is predominantly higher in severe Covid-19 patients compared with the heterozygous (GA) genotype (41.7%). In our study, only one homozygous mutant (AA) genotype (0.8%) was unexpectedly found in a mild case who was female, old without comorbidities. It appears that the AA genotype is more prevalent in the Egyptian population studied by Saleh et al. than the Kurdish population in the current study. The homozygous mutant (AA) genotype tends to be rare in the Kurdish ethnic background. Therefore, other ethnic populations should be investigated for TNF-α −308G>A SNP in association with Covid-19. In a Mexican population, TNF receptors (TNFR1 and TNFR2) are associated with Covid-19 and, both soluble TNFR1 and TNFRSF1A:rs767455 variants are high in severe patients. In the current study, the frequency of TNF-α genotypes and alleles, comparing between mild and moderate/severe groups were not statistically significant (Table 4). Similarly, no significant differences were found according to genders (Table 5), ages (Table 6), comorbidities (Table 7). Our cohort data are adequate to support that the heterozygous (GA) genotype, which was statistically significant in comparing between patient and control groups, might be associated with Covid-19 susceptibility (Table 3).

Studies showed that pro-inflammatory cytokines circulating in plasma, particularly TNF-α, are associated with severe Covid-19 infection, while others do not support this. However, genetic polymorphisms have not been taken into consideration in these studies. Thus, genetic studies along with both serological tests and in vitro studies should be combined in the future to solve these discrepancies. Gene knockout mouse studies showed that TNF-α acts as a pro-inflammatory cytokine in an initial response to infections, however, it plays also an immunoregulatory role post-infection. It has been observed that most severe or symptomatic Covid-19 patients usually have an initial pro-inflammatory response which is then followed by immune dysregulations reducing hyperinflammation, cytokine storm, and ARDS in severe patients. Genetic defects in genes (e.g., TNF-α −308 SNP) may modify inflammatory profiles that lead to severe outcomes in severe Covid-19 patients. Thus, studying polymorphisms in the promoter region of the TNF-α gene that enhances its expression will broaden our knowledge on why some Covid-19 patients are more susceptible to SARS CoV-2. It could be hypothesized that the TNF SNP plays a role in the increasing secretion of a high amount of TNF-α protein in severe Covid-19 patients that cause immune dysregulation and organ damage.

The limitations of the current study were that we have not tested other SNPs in the promoter region of the TNF-α gene. It is intriguing to report the co-occurrence of other TNF-α SNPs in severe Covid-19 cases who are young and have no other diseases. It is recommended that young healthy individuals suffering from severe Covid-19 should be included in studies for discovering rare genetic variants which play roles in the severity. A recent study has reported TLR7 genetic variants in severe young male Covid-19 patients with no comorbidities. It seems more interesting to perform whole genome or exome sequencing in young case reports who were previously healthy and currently suffered from severe Covid-19 for exploring multi genetic variations in the same patient.

5 | CONCLUSION

In the current study, the heterozygous genotype of the TNF-α −308 G>A SNP was significantly higher in the Covid-19 patient group in an Iraqi Kurdish population compared with that of the general population. This suggested that this SNP might be associated with Covid-19 infection. However, a larger number of samples are needed to confirm this. Investigations of other TNF-α SNPs are recommended for future studies including 1031T>C, 863C>A, 857C>A, 851C>T, 419G>C, 376G>A, 238G>A, 162G>A, and 49G>A.

ACKNOWLEDGEMENT

We are very grateful to Sheikh Hassan Talabani for his charity support to construct the Coronavirus Research and Identification Lab.
CONFICT OF INTEREST

All authors have no conflict of interest to declare.

AUTHOR CONTRIBUTIONS

HNA, SSN, and SAMA carried out conceptualization, design analysis, planning, and editing the manuscript. HNA carried out sample collections and clinical data. SSN and SAMA carried out genotyping and drafting the article. SAMA carried out statistical analysis.

DATA AVAILABILITY STATEMENT

All data are available through corresponding author, Sherko S. Niranji.

ORCID

Sherko S. Niranji https://orcid.org/0000-0001-9210-0129

REFERENCES

1. Bhardwaj A, Sapra L, Saini C, et al. COVID-19: immunology, immunopathogenesis and potential therapies. Int Rev Immunol. 2022;41(2):171-206. doi:10.1080/08830185.2021.1883600
2. Pojero F, Candore G, Caruso C, et al. The role of immunogenetics in COVID-19. Int J Mol Sci. 2021;22(5):2636. doi:10.3390/ijms20252636
3. Abobaker A, Nagib T, Alsoufi A. The impact of certain genetic variants (single nucleotide polymorphisms) on incidence and severity of COVID-19. J Gene Med. 2021;23(2):e3310. doi:10.1002/jgm.3310
4. Santos ACM, dos Santos BRC, dos Santos BB, et al. Genetic polymorphisms as multi-biomarkers in Severe Acute Respiratory Syndrome (SARS) by coronavirus infection: a systematic review of candidate gene association studies. Infect Genet Evol. 2021;93:104846. doi:10.1016/j.meegid.2021.104846
5. Ghafouri-Fard S, Noroozi R, Vafaee R, et al. Effects of host genetic variations on response to, susceptibility and severity of respiratory infections. Biomed Pharmacother. 2020;120:110296. doi:10.1016/j.biopha.2020.110296
6. Niemi MEK, Karjalainen J, Liao RG, et al. Mapping the human genetic architecture of COVID-19. Nature. 2021;600(7889):472-477. doi:10.1038/s41586-021-03767-x
7. Kousathanas A, Pairo-Castineira E, Rawlik K, et al. Whole genome sequencing reveals host factors underlying critical COVID-19. Nature. 2022. doi:10.1038/s41586-022-04576-6. Online ahead print.
8. Ferreira de Araújo JL, Menezes D, Saraiva-Duarte JM, de Lima Ferreira L, Santana de Aguiar R, Pedro de Souza R. Systematic review of host genetic association with COVID-19 prognosis and susceptibility: what have we learned in 2020? Rev Med Virol. 2022;32(2):e2283. doi:10.1002/rmv.2283
9. Qidwai T, Khan F. Tumor necrosis factor gene polymorphism and disease prevalence. Scand J Immunol. 2011;74(6):522-547. doi:10.1111/j.1365-3083.2011.02602.x
10. El-Tahan RR, Ghoneim AM, El-Mashad N. TNF-α gene polymorphisms and expression. SpringerPlus. 2016;5(1):1508. doi:10.1186/s40064-016-3197-y
11. Zhang Y, Cui X, Ning L, Wei D. The effects of Tumor Necrosis Factor-α (TNF-α) rs1800629 and rs361525 polymorphisms on sepsis risk. Oncotarget. 2017;8(67):111456-111469. doi:10.18632/oncotarget.22824
12. Watanabe E, Zehn Bauer BA, Oda S, Sato Y, Hirase wa H, Buchman TG. Tumor necrosis factor -308 polymorphism (rs1800629) is associated with mortality and ventilator duration in 1057 Caucasian patients. Cytokine. 2012;60(1):249-256. doi:10.1016/j.cyto.2012.06.016
13. Elahi MM, Asotra K, Matata BM, Mastana SS. Tumor necrosis factor alpha -308 gene locus promoter polymorphism: an analysis of association with health and disease. Biochim Biophys Acta. 2009;1792(3):163-172. doi:10.1016/j.bbdis.2009.01.007
14. Bucardo F, Reyes Y, Morales M, et al. Association of genetic polymorphisms in DC-SIGN, toll-like receptor 3, and tumor necrosis factor α genes and the Lewis-negative phenotype with chikungunya infection and disease in Nicaragua. J Infect Dis. 2021;223(2):278-286. doi:10.1093/infdis/jiaa364
15. Santos ACM, de Moura EL, Ferreira JM, et al. Meta-analysis of the relationship between TNF-α (-308G/A) and IL-10 (-819C/T) gene polymorphisms and susceptibility to dengue. Immunol Invest. 2017;46(2):201-220. doi:10.1080/08822139.2016.1248560
16. Doga G, Chakravarti A, Kar P, Chawila YK. Polymorphism of tumor necrosis factor-alpha and interleukin-10 gene promoter region in chronic hepatitis C virus patients and their effect on pegylated interferon alpha therapy response. Hum Immunol. 2011;72(10):935-939. doi:10.1016/j.humimm.2011.06.008
17. Forbester JL, Humphreys IR. Genetic influences on viral-induced cytokine responses in the lung. Mucosal Immunol. 2014;1(14):24-25. doi:10.1038/s41385-020-00355-6
18. Niranji SS. Genetic polymorphism of toll-like receptor 4 Thr399Ile variant in Iraqi Kurdish population: sulaymaniyah province. Passer J Basic Appl Sci. 2020;2(1):32-36. doi:10.24271/pxs08
19. Al-Jaf SMA, Niranji SS, AliHN, Mohammed OA. Association of Apolipoprotein e polymorphism with SARS-CoV-2 infection. Infect Genet Evol. 2021;95:105043. doi:10.1016/j.meegid.2021.105043
20. Saleh A, Sultan A, Elashry MA, et al. Association of TNF-α G-308A promoter polymorphism with the course and outcome of COVID-19 patients. Immunol Invest. 2020;50(7):735-739. doi:10.1080/08822139.2019.1851709
21. Palacios Y, Ruiz A, Ramón-Luín LA, et al. Severe COVID-19 patients show an increase in soluble TNFR1 and ADAM17, with a relationship to mortality. Int J Mol Sci. 2021;22(16):8423. doi:10.3390/ijms22168423
22. Banday MZ, Balkhi HM, Hamid Z, Sameer AS, Chowdri NA, Haq E. Tumor Necrosis Factor-α (TNF-α)-308G/A promoter polymorphism in colorectal cancer in ethnic Kashmiri population - A case control study in a detailed perspective. Meta Gene. 2016;9:128-136. doi:10.1016/j.mgene.2016.06.001
23. Del Valle DM, Kim-Schulze S, Huang H-H, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10):1636-1643. doi:10.1038/s41591-020-1051-9
24. Dorgham K, Quentin C, Gökkyaya M, et al. Distinct cytokine profiles associated with COVID-19 severity and mortality. J Allergy Clin Immunol. 2021;147(6):2098-2107. doi:10.1016/j.jaci.2021.03.047
25. Guo Y, Li T, Xia X, et al. Different profiles of antibodies and cytokines were found between severe and moderate COVID-19 patients. Front Immunol. 2021;12:23585. doi:10.3389/fimmu.2021.723585
26. Liu QQ, Cheng A, Wang Y, et al. Cytokines and their relationship with the severity and prognosis of Coronavirus Disease 2019 (COVID-19): a retrospective cohort study. BMJ Open. 2020;10(11):e041471. doi:10.1136/bmjopen-2020-041471
27. Udomsinsrartert W, Jittikoon J, Sangroongruangsri S, Chakladkaew U. Circulating levels of interleukin-6 and interleukin-10, but not tumor necrosis factor-alpha, as potential biomarkers of severity and mortality for COVID-19: systematic review with meta-analysis. J Clin Immunol. 2021;41(1):11-22. doi:10.1007/s10875-020-00899-z
28. Wilson JG, Simpson LJ, Ferreira A-M, et al. Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis. *JCI Insight*. 2020;5(17):e140289. doi:10.1172/jci.insight.140289

29. Solanich X, Vargas-Parra G, van der Made CI, et al. Genetic screening for TLR7 variants in young and previously healthy men with severe COVID-19. *Front Immunol*. 2021;12:719115. doi:10.3389/fimmu.2021.719115

30. Al-Jaf SM. Frequencies of Apolipoprotein E polymorphism in Iraqi Kurdish population. *Meta Gene*. 2021;28:100867. doi:10.1016/j.mgene.2021.100867

How to cite this article: Ali HN, Niranji SS, Al-Jaf SMA. Association of tumor necrosis factor alpha -308 single nucleotide polymorphism with SARS CoV-2 infection in an Iraqi Kurdish population. *J Clin Lab Anal*. 2022;36:e24400. doi:10.1002/jcla.24400